Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. on November 17, 2025. The filing discloses the appointment of a new executive officer under Item 5.02.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Kristian Humer as Chief Financial Officer and Principal Financial Officer, effective November 17, 2025. Mr. Humer previously served as CFO at Foghorn Therapeutics, Inc. (April 2024 – November 2025) and held various roles at Citigroup Global Markets Inc. (2010 – 2021).
Management Commentary and Compensation Details
The filing details the compensatory arrangements for the new CFO as outlined in the Offer Letter:
- Base Salary: $520,000 per year.
- Performance Bonus: Discretionary annual bonus with a target of 40% of base salary.
- Equity Grant: Stock option to purchase 480,000 shares of common stock.
- Sign-on Bonus: $100,000 aggregate, payable in two equal installments. The first installment is paid shortly after the start date but is not deemed earned until the one-year anniversary of payment. The second installment is paid after the one-year anniversary of the start date, subject to continued employment, and is not deemed earned until the one-year anniversary of payment.
- Severance:
- Termination without cause or for good reason: 9 months of base salary plus COBRA reimbursement for up to 9 months.
- Termination within 12 months after a change in control: 12 months of base salary, COBRA reimbursement for up to 12 months, and full vesting acceleration of outstanding equity awards.
Severance benefits are conditioned on the execution of a general release agreement and compliance with confidentiality agreements.
Investor Verification Checklist
- Verify the vesting schedule and exercise terms for the 480,000 stock options granted to Mr. Humer.
- Confirm the specific dates for the two installments of the $100,000 sign-on bonus.
- Review the Company's standard indemnification agreement referenced in the filing.
- Monitor future filings for any changes to the Company's financial leadership or strategy resulting from this appointment.